

# Filippo de Braud

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7230534/filippo-de-braud-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

445  
papers

21,420  
citations

68  
h-index

134  
g-index

464  
ext. papers

25,502  
ext. citations

5.7  
avg, IF

6.32  
L-index

#	Paper	IF	Citations
445	Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 663-71	2.2	1360
444	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1877-88	59.2	1195
443	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , <b>2015</b> , 386, 444-51	40	926
442	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 883-895	21.7	783
441	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1535-1546	10.3	572
440	Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1465-71	2.2	526
439	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , <b>2013</b> , 45, 1470-1473	36.3	464
438	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1590-1598	21.7	450
437	Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. <i>Annals of Oncology</i> , <b>2002</b> , 13, 73-80	10.3	373
436	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 587-94	7.5	329
435	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 71, 127-64	7	316
434	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2836-2844	2.2	296
433	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , <b>2017</b> , 552, 116-120	50.4	290
432	Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. <i>Cancer Discovery</i> , <b>2016</b> , 6, 492-500	24.4	245
431	Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. <i>Cancer Research</i> , <b>2005</b> , 65, 2964-71	10.1	234
430	Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3217-23	2.2	219
429	Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2372-7	2.2	216

428	Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. <i>Annals of Oncology</i> , <b>1998</b> , 9, 767-73	10.3	206
427	Caring for patients with cancer in the COVID-19 era. <i>Nature Medicine</i> , <b>2020</b> , 26, 665-671	50.5	201
426	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5407-15	2.2	198
425	Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 102-9	2.2	196
424	Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 813-824	59.2	194
423	Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. <i>Annals of Oncology</i> , <b>1998</b> , 9, 105-8	10.3	185
422	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 165-171	8.7	174
421	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2010</b> , 74, 106-33	7	172
420	Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2001</b> , 28, 426-34		167
419	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 237-244	8.9	163
418	Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3733-40	2.2	159
417	Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. <i>Annals of Oncology</i> , <b>2009</b> , 20, 935-40	10.3	157
416	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 261-270	21.7	154
415	Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. <i>Cancer</i> , <b>2004</b> , 101, 1302-10	6.4	151
414	Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1999</b> , 26, 348-57	8.8	150
413	Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 1867-74	2.2	148
412	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. <i>Oncotarget</i> , <b>2014</b> , 5, 2839-52	3.3	134
411	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2244-2251	10.3	133

410	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	126
409	The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 2926-35	7.5	125
408	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 5505-5516	15.9	120
407	Dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1234-1243	21.7	120
406	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 810-6	21.7	119
405	A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7732-42	12.9	116
404	Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. <i>European Journal of Cancer</i> , <b>2004</b> , 40, 1872-7	7.5	115
403	A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. <i>Cancer</i> , <b>2001</b> , 92, 1204-12	6.4	114
402	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1319-1327	8.9	112
401	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2414-2422	12.9	111
400	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2092-7	10.3	110
399	Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. <i>Endocrine-Related Cancer</i> , <b>2007</b> , 14, 473-82	5.7	110
398	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1608-1616	2.2	108
397	Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1315-1333	24.1	107
396	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 511-521	4.9	107
395	Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2604-11	2.2	101
394	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 497-507	21.7	98
393	Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1895-901	8.9	96

392	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 426-435	8.9	96
391	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , <b>2019</b> , 4, e000457	6	93
390	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1994-1999	10.3	93
389	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. <i>American Journal of Transplantation</i> , <b>2016</b> , 16, 2892-2902	8.7	93
388	Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. <i>European Journal of Cancer</i> , <b>1997</b> , 33, 1190-4	7.5	92
387	Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications?. <i>Annals of Thoracic Surgery</i> , <b>2004</b> , 77, 260-5; discussion 265	2.7	87
386	Fasting-mimicking diet and hormone therapy induce breast cancer regression. <i>Nature</i> , <b>2020</b> , 583, 620-624	10.4	79
385	Cancer of the prostate. <i>Critical Reviews in Oncology/Hematology</i> , <b>2005</b> , 56, 379-96	7	78
384	Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. <i>Critical Reviews in Oncology/Hematology</i> , <b>2008</b> , 65, 1-7	7	76
383	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , <b>2016</b> , 21, 988-94	5.7	72
382	Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2014</b> , 41, 223-30	8.8	72
381	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 963-71	24.4	71
380	Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2013</b> , 139, 447-55	4.9	70
379	Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?. <i>Annals of Oncology</i> , <b>2007</b> , 18, 13-19	10.3	70
378	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 139, 53-66	7	68
377	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 196	4.8	68
376	miR-9 and miR-200 Regulate PDGFR-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. <i>Cancer Research</i> , <b>2016</b> , 76, 5562-72	10.1	67
375	A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 290-6	7.5	66

374	Real-world study of everolimus in advanced progressive neuroendocrine tumors. <i>Oncologist</i> , <b>2014</b> , 19, 966-74	5.7	66
373	Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. <i>Biopharmaceutics and Drug Disposition</i> , <b>2001</b> , 22, 191-7	1.7	66
372	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2005</b> , 54, 209-41	7	65
371	Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. <i>Annals of Thoracic Surgery</i> , <b>2005</b> , 79, 234-40	2.7	64
370	A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1413-1419	10.3	63
369	Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. <i>Cancer</i> , <b>1995</b> , 75, 1649-56	6.4	62
368	Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. <i>Oncotarget</i> , <b>2016</b> , 7, 4428-41	3.3	62
367	Targeting the MET gene for the treatment of non-small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 89, 284-99	7	61
366	Breast cancer vaccines: a clinical reality or fairy tale?. <i>Annals of Oncology</i> , <b>2006</b> , 17, 750-62	10.3	61
365	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 833-40	7.5	60
364	Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. <i>Cancer</i> , <b>2006</b> , 107, 2474-81	6.4	59
363	Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. <i>Pharmacological Reviews</i> , <b>2003</b> , 55, 57-103	22.5	58
362	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1082-1089	12.9	58
361	HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 2859-2864	7.5	57
360	Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1686-90	8.7	56
359	Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. <i>Journal of Gastrointestinal Oncology</i> , <b>2017</b> , 8, 148-163	2.8	54
358	Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. <i>Lung Cancer</i> , <b>2012</b> , 77, 507-14	5.9	54
357	Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. <i>Breast Cancer Research and Treatment</i> , <b>2005</b> , 93, 25-40	4.4	53

356	Pharmacogenetic determinants of anti-cancer drug activity and toxicity. <i>Trends in Pharmacological Sciences</i> , <b>2001</b> , 22, 420-6	13.2	52
355	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. <i>Annals of Oncology</i> , <b>2014</b> , 25, 404-8	10.3	51
354	Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. <i>Annals of Oncology</i> , <b>2008</b> , 19, 173-7	10.3	51
353	Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 72, 45-55	14.4	51
352	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 96, 156-66	7	50
351	Malignant melanoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2003</b> , 47, 35-63	7	50
350	A review on biomarkers for prediction of treatment outcome in gastric cancer. <i>Anticancer Research</i> , <b>2013</b> , 33, 1257-66	2.3	48
349	Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 1153-1161	7.5	47
348	Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1964-72	12.9	47
347	Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. <i>PLoS ONE</i> , <b>2014</b> , 9, e108940	3.7	46
346	p63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. <i>International Journal of Surgical Pathology</i> , <b>2013</b> , 21, 229-39	1.2	46
345	Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1597-603	10.3	45
344	Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. <i>Neuroendocrinology</i> , <b>2012</b> , 96, 32-40	5.6	44
343	Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. <i>Annals of Oncology</i> , <b>1999</b> , 10, 1311-6	10.3	42
342	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 80, 581-8	3.8	41
341	Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. <i>Oncology</i> , <b>2008</b> , 74, 177-87	3.6	41
340	Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 938-41	8.9	41
339	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 800-7	7.5	40

338	Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. <i>Annals of Oncology</i> , <b>2015</b> , 26, 657-668	10.3	39
337	Better Together: Targeted Combination Therapies in Breast Cancer. <i>Seminars in Oncology</i> , <b>2015</b> , 42, 887-95	9.5	39
336	Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells. <i>Oncotarget</i> , <b>2015</b> , 6, 5275-91	3.3	39
335	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151662	3.7	39
334	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor $\alpha$ (TGF $\alpha$ ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 555-60	4.3	38
333	Role of cMET in the development and progression of colorectal cancer. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 18056-77	6.3	38
332	5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. <i>Annals of Oncology</i> , <b>2004</b> , 15, 759-64	10.3	38
331	The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. <i>Cell Adhesion and Migration</i> , <b>2015</b> , 9, 14-21	3.2	37
330	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1268-1275	13.4	37
329	FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. <i>Oncologist</i> , <b>2014</b> , 19, 845-50	5.7	37
328	In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. <i>British Journal of Cancer</i> , <b>2006</b> , 95, 289-97	8.7	37
327	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , <b>2018</b> , 155, 479-489.e7	13.3	36
326	Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. <i>Current Drug Targets</i> , <b>2015</b> , 16, 164-70	3	36
325	Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. <i>European Journal of Surgical Oncology</i> , <b>2017</b> , 43, 380-387	3.6	35
324	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3099-3110	2.2	35
323	Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 494-500	7.5	35
322	First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. <i>Cancer</i> , <b>2007</b> , 110, 752-8	6.4	35
321	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. <i>Lung Cancer</i> , <b>2019</b> , 132, 72-78	5.9	34

320	Treatment of lung large cell neuroendocrine carcinoma. <i>Tumor Biology</i> , <b>2016</b> , 37, 7047-57	2.9	34
319	Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 484-8	3.3	34
318	Gemcitabine-induced systemic capillary leak syndrome. <i>Annals of Oncology</i> , <b>2001</b> , 12, 1651-2	10.3	34
317	Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1998</b> , 21, 279-83	2.7	34
316	Treatment of carcinoid syndrome with recombinant interferon alpha-2a. <i>Acta Oncologica</i> , <b>1993</b> , 32, 235-8	3.2	33
315	Lymphoma Immunotherapy: Current Status. <i>Frontiers in Immunology</i> , <b>2015</b> , 6, 448	8.4	32
314	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 1228-37	3.8	32
313	Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 72, 110-24	7	32
312	Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). <i>European Journal of Cancer</i> , <b>2020</b> , 137, 272-284	7.5	32
311	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. <i>Cancer Treatment Reviews</i> , <b>2010</b> , 36 Suppl 3, S87-94	14.4	31
310	High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?. <i>Annals of Oncology</i> , <b>1998</b> , 9, 917-9	10.3	31
309	Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. <i>Acta Oncologica</i> , <b>2010</b> , 49, 117-9	3.2	30
308	Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 421-7	4	30
307	Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 2116-22	7.5	30
306	Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4966-70	2.2	30
305	Characterization of the response of human thymocytes and blood lymphocytes to the synergistic mitogenicity of 12-O-tetradecanoylphorbol-13-acetate (TPA)-ionomycin. <i>European Journal of Immunology</i> , <b>1984</b> , 14, 720-4	6.1	30
304	A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. <i>Oncotarget</i> , <b>2015</b> , 6, 5118-33	3.3	30
303	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , <b>2015</b> , 20, 1261-5	5.7	29

302	HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. <i>Blood</i> , <b>2015</b> , 125, 1768-71	2.2	29
301	$^{18}$ F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 818-30	8.8	29
300	Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. <i>Annals of Oncology</i> , <b>2002</b> , 13, 895-902	10.3	29
299	Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2001</b> , 12, 1553-9	10.3	29
298	Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 50-59	4.9	28
297	Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. <i>Annals of Oncology</i> , <b>2016</b> , 27, 668-73	10.3	28
296	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6-6	2.2	28
295	Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?. <i>Oncology</i> , <b>2013</b> , 84, 191-9	3.6	27
294	Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. <i>Annals of Oncology</i> , <b>1997</b> , 8, 865-70	10.3	27
293	Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1998</b> , 25, 1336-9	8.8	27
292	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2004</b> , 51, 145-70	7	27
291	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. <i>Oncotarget</i> , <b>2016</b> , 7, 3947-65	3.3	27
290	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 2858	4.9	26
289	Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 123, 57-73	7	26
288	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 125	8.5	26
287	Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 197-203	14.4	26
286	Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 837-44	8.7	26
285	Diagnosis and management of typical and atypical lung carcinoids. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 100, 167-76	7	26

284	MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 650	5.3	26
283	Osteopontin, E-cadherin, and E-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , <b>2016</b> , 19, 412-420	7.6	25
282	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 1467-74	7.5	25
281	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , <b>2016</b> , 1, e000127	6	25
280	Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2015</b> , 38, 479-82 <sup>2-7</sup>		25
279	Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2000</b> , 11, 821-7	10.3	25
278	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 117, 315-21	5.3	24
277	A catalyst for change: the European cancer Patient's Bill of Rights. <i>Oncologist</i> , <b>2014</b> , 19, 217-24	5.7	24
276	Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2012</b> , 83, 432-43	7	24
275	Bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2002</b> , 41, 89-106	7	24
274	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. <i>Oncotarget</i> , <b>2017</b> , 8, 16887-16898	3.3	24
273	A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2341-6	10.3	23
272	Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1782-7	10.3	23
271	Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. <i>Annals of Thoracic Surgery</i> , <b>2007</b> , 83, 231-4	2.7	23
270	Identification and characterization of a novel rearrangement in a colorectal cancer patient. <i>Oncotarget</i> , <b>2017</b> , 8, 55353-55360	3.3	23
269	Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. <i>Lung Cancer</i> , <b>2018</b> , 115, 135-142 <sup>5-9</sup>		23
268	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2017</b> , 71, 43-50	7.5	22
267	Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study. <i>Clinical Breast Cancer</i> , <b>2017</b> , 17, 219-231	3	22

266	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 347-352	8.7	22
265	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 1098-103	4.6	22
264	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1253-1263	2.2	22
263	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1560-9	8.9	21
262	Role of MGMT as biomarker in colorectal cancer. <i>World Journal of Clinical Cases</i> , <b>2014</b> , 2, 835-9	1.6	21
261	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , <b>2016</b> , 34, 236-42	4.3	20
260	Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. <i>British Journal of Cancer</i> , <b>2003</b> , 89 Suppl 2, S19-23	8.7	20
259	Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). <i>Annals of Oncology</i> , <b>1999</b> , 10, 993-6	10.3	20
258	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , <b>2019</b> , 2, 699-707	6.7	19
257	Preoperative chemotherapy is essential for conservative surgery of Askin tumors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2003</b> , 125, 428-9	1.5	19
256	Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. <i>Oncology</i> , <b>1995</b> , 52, 41-4	3.6	19
255	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab + Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3926-3935	12.9	19
254	A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2146-54	12.9	19
253	Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. <i>Thrombosis Research</i> , <b>2016</b> , 140 Suppl 1, S55-9	8.2	19
252	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. <i>Future Oncology</i> , <b>2016</b> , 12, 1251-60	3.6	19
251	MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S393-S394	8.9	18
250	Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 160, 425-437	4.4	18
249	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , <b>2016</b> , 11, 337-43	5	18

248	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , <b>2015</b> , 32, 182	3.7	18
247	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1227-32	8.7	18
246	Practical considerations in the treatment of hepatocellular carcinoma. <i>Drugs</i> , <b>1998</b> , 55, 367-82	12.1	18
245	Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , <b>2015</b> , 7, 152-61	3.2	17
244	miR-205 mediates adaptive resistance to MET inhibition via ERRF1 targeting and raised EGFR signaling. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,	12	17
243	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. <i>PLoS ONE</i> , <b>2014</b> , 9, e92147	3.7	17
242	"Waiting and the waiting room: how do you experience them?" emotional implications and suggestions from patients with cancer. <i>Journal of Cancer Education</i> , <b>2011</b> , 26, 388-94	1.8	17
241	Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study. <i>Strahlentherapie Und Onkologie</i> , <b>2005</b> , 181, 363-71	4.3	17
240	Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. <i>Lung Cancer</i> , <b>2001</b> , 31, 267-70	5.9	17
239	Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors. <i>Acta Oncologica</i> , <b>1993</b> , 32, 245-50	3.2	17
238	Neuroendocrine tumour arising inside a retro-rectal tailgut cyst: report of two cases and a review of the literature. <i>Ecancermedalscience</i> , <b>2011</b> , 5, 201	2.7	17
237	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	17
236	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 98, 24-8	7	16
235	Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , <b>2019</b> , 5, 217-226	5.3	16
234	Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 137-41	3.3	16
233	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 26-33	8.7	16
232	Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. <i>Pharmacogenomics Journal</i> , <b>2010</b> , 10, 180-90	3.5	16
231	Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. <i>Prostate</i> , <b>2007</b> , 67, 603-4	4.2	16

230	Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung. <i>Lung Cancer</i> , <b>2005</b> , 48, 233-40	5.9	16
229	Cancer of pancreas. <i>Critical Reviews in Oncology/Hematology</i> , <b>2004</b> , 50, 147-55	7	16
228	Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 105, 52-64	7	16
227	Immunotherapy-based combinations: an update. <i>Current Opinion in Oncology</i> , <b>2018</b> , 30, 345-351	4.2	16
226	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. <i>Annals of Oncology</i> , <b>2015</b> , 26, 838-847	10.3	15
225	Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. <i>Patient Preference and Adherence</i> , <b>2013</b> , 7, 391-400	2.4	15
224	Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. <i>Clinical Breast Cancer</i> , <b>2004</b> , 5, 125-30	3	15
223	Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. <i>Annals of Oncology</i> , <b>2002</b> , 13, 161-6	10.3	15
222	Expression of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other B-cell differentiation markers. <i>Hematological Oncology</i> , <b>1986</b> , 4, 237-48	1.3	15
221	Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patients. <i>Cancer Discovery</i> , <b>2021</b> ,	24.4	15
220	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , <b>2021</b> , 150, 155-167	7.5	15
219	Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. <i>Drug Design, Development and Therapy</i> , <b>2016</b> , 10, 2167-72	4.4	15
218	Exploiting Fasting-mimicking Diet and METformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e413-e417	4.9	15
217	Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 203-209.e1	3.3	14
216	Experience with sorafenib in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , <b>2012</b> , 4, 303-13	3.2	14
215	Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?. <i>Oncology</i> , <b>2003</b> , 64, 186-8	3.6	14
214	Drug-induced prolongation of the QT interval. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 2618-21; author reply 2618-21	59.2	14
213	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 33	8.3	14

212	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Targeted Oncology</i> , <b>2018</b> , 13, 795-800	5	14
211	Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 8884-95	6.3	13
210	Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 95, 272-81	7	13
209	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 88, 102057	14.4	13
208	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, 607-618	5.7	13
207	Challenging Lung Carcinoma with Coexistent Np63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1500-2	8.9	13
206	BRAF in metastatic colorectal cancer: the future starts now. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 2069-81	2.6	13
205	Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. <i>Cancers</i> , <b>2014</b> , 6, 1753-68	6.6	13
204	Bax expression is predictive of favorable clinical outcome in chemo-naïve advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. <i>Translational Oncology</i> , <b>2012</b> , 5, 155-9	4.9	13
203	Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey. <i>Tumori</i> , <b>2009</b> , 95, 647-651	1.7	13
202	"Burned out" phenomenon of the testis in retroperitoneal seminoma. <i>Acta Oncologica</i> , <b>2006</b> , 45, 335-6	3.2	13
201	Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. <i>Tumori</i> , <b>2014</b> , 100, e286-9	1.7	13
200	Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2016</b> , 468, 651-62	5.1	13
199	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 332.e19-24	2.8	12
198	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. <i>Tumor Biology</i> , <b>2016</b> , 37, 12991-13003	2.9	12
197	A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer. <i>Acta Oncologica</i> , <b>2010</b> , 49, 480-4	3.2	12
196	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 70, 160-82	7	12
195	Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1174-5	10.3	12

194	Hyperfractionated radiotherapy in locally advanced nasopharyngeal cancer. An analysis of 43 consecutive patients. <i>Strahlentherapie Und Onkologie</i> , <b>2004</b> , 180, 425-33	4.3	12
193	START: a European state-of-the-art on-line instrument for clinical oncologists. <i>Annals of Oncology</i> , <b>1999</b> , 10, 769-73	10.3	12
192	Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. <i>European Journal of Cancer</i> , <b>1994</b> , 30A, 596-600	7.5	12
191	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 156-164	3.8	12
190	Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
189	Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	12
188	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 465-472	3.5	11
187	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , <b>2019</b> , 132, 17-23	5.9	11
186	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 100, 99-106	7	11
185	Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis. <i>Supportive Cancer Therapy</i> , <b>2006</b> , 3, 98-102		11
184	Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer. <i>Tumori</i> , <b>2016</b> , 102, e11-4	1.7	11
183	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , <b>2021</b> , 152, 165-173 <sup>5.9</sup>		11
182	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. <i>Cancers</i> , <b>2019</b> , 11,	6.6	10
181	Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e735-e742	3.3	10
180	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 955-965	8.7	10
179	Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. <i>Therapeutic Advances in Medical Oncology</i> , <b>2016</b> , 8, 323-30	5.4	10
178	Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 63, 139-48	3.5	10
177	Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 131-134	8.9	10

176	A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 3495-3503	7.5	10
175	Fasting-mimicking diet plus chemotherapy in breast cancer treatment. <i>Nature Communications</i> , <b>2020</b> , 11, 4274	17.4	10
174	Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 576-585	7.5	10
173	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 60, 344-350	12.7	10
172	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , <b>2017</b> , 6, 1493-1499	4.8	9
171	Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. <i>Future Oncology</i> , <b>2015</b> , 11, 1947-59	3.6	9
170	Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 1047-1068	2.6	9
169	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , <b>2017</b> , 16, e191-e198	3.8	9
168	Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 301-6	3.5	9
167	Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group. <i>British Journal of Cancer</i> , <b>2003</b> , 88, 645-7	8.7	9
166	Ifosfamide in the elderly: clinical considerations for a better drug management. <i>Critical Reviews in Oncology/Hematology</i> , <b>2000</b> , 33, 129-35	7	9
165	COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study. <i>ESMO Open</i> , <b>2020</b> , 5,	6	9
164	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. <i>Oncotarget</i> , <b>2016</b> , 7, 44841-44847	3.3	9
163	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , <b>2017</b> , 49, 834-845	5.2	9
162	The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy. <i>Targeted Oncology</i> , <b>2021</b> , 16, 529-536	5	9
161	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. <i>Clinical Breast Cancer</i> , <b>2019</b> , 19, e306-e318	3	9
160	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , <b>2019</b> , 144, 1704-1712	7.5	9
159	Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , <b>2019</b> , 4, e000489	6	8

158	Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 171-7.e1	3.3	8
157	Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?. <i>Tumori</i> , <b>2016</b> , 102, 18-30	1.7	8
156	Safety profile and treatment response of everolimus in different solid tumors: an observational study. <i>Future Oncology</i> , <b>2014</b> , 10, 1611-7	3.6	8
155	TP53 mutations in advanced colorectal cancer: the dark side of the moon. <i>Oncology</i> , <b>2014</b> , 86, 289-94	3.6	8
154	Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. <i>Annals of Oncology</i> , <b>2009</b> , 20, 498-502	10.3	8
153	Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. <i>Oncology</i> , <b>2009</b> , 77, 358-65	3.6	8
152	QTc prolongation assessment in anticancer drug development: clinical and methodological issues. <i>Ecancermedicalscience</i> , <b>2009</b> , 3, 130	2.7	8
151	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2004</b> , 51, 121-43	7	8
150	Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required?. <i>Annals of Oncology</i> , <b>2000</b> , 11, 117-8	10.3	8
149	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1017-1024	12.9	8
148	Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 949-54	2.4	8
147	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. <i>Haematologica</i> , <b>2020</b> , 105, 1704-1711	6.6	8
146	The role of metastasectomy in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2019</b> , 19, 603-611	3.5	7
145	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e179-e190	3.8	7
144	Role of BAX for outcome prediction in gastrointestinal malignancies. <i>Medical Oncology</i> , <b>2013</b> , 30, 610	3.7	7
143	Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , <b>2003</b> , 44 Suppl 3, S115-22	1.9	7
142	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 82, 101935	14.4	7
141	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. <i>Cancer Letters</i> , <b>2021</b> , 511, 77-87	9.9	7

140	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. <i>Pharmacogenomics Journal</i> , <b>2017</b> , 17, 331-336	3.5	6
139	Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. <i>Endocrine</i> , <b>2017</b> , 57, 512-517	4	6
138	Thrombin generation predicts early recurrence in breast cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2220-2231	15.4	6
137	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 230-239	7.5	6
136	Improved health perception after genetic counselling for women at high risk of breast and/or ovarian cancer: construction of new questionnaires--an Italian exploratory study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2016</b> , 142, 633-48	4.9	6
135	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality.. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-14	3.6	6
134	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , <b>2017</b> , 2, e000241	6	6
133	Phase Ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. <i>Oncologist</i> , <b>2014</b> , 19, 344-5	5.7	6
132	Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. <i>International Journal of Surgical Pathology</i> , <b>2014</b> , 22, 136-48	1.2	6
131	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , <b>2014</b> , 10, 1361-72	3.6	6
130	Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. <i>Future Oncology</i> , <b>2013</b> , 9, 1599-607	3.6	6
129	Miliary hepatic metastases from neuroendocrine carcinoma. <i>Digestive Surgery</i> , <b>2008</b> , 25, 330	2.5	6
128	Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma. <i>Acta Oncologica</i> , <b>2006</b> , 45, 627-9	3.2	6
127	Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. <i>Supportive Care in Cancer</i> , <b>2005</b> , 13, 194-5	3.9	6
126	Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550): ... and in humans?. <i>Annals of Oncology</i> , <b>2005</b> , 16, 673	10.3	6
125	Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 388-388	2.2	6
124	5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 16437-16450	3.3	6
123	HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature. <i>Breast Care</i> , <b>2016</b> , 11, 424-426	2.4	6

122	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , <b>2019</b> , 107, 164-174	7.5	6
121	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 116-124	3.8	5
120	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 78-88	7.5	5
119	Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections. <i>HemaSphere</i> , <b>2020</b> , 4, e408	0.3	5
118	Uncommon somatic mutations in metastatic NUT midline carcinoma. <i>Tumori</i> , <b>2017</b> , 103, e5-e8	1.7	5
117	Improved quality of life is the way to longer life. <i>Lancet Oncology</i> , <b>2016</b> , 17, 862-863	21.7	5
116	Treatment of elderly patients with metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 323-34	3.5	5
115	Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1017-8	2.2	5
114	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. <i>Future Oncology</i> , <b>2019</b> , 15, 2743-2757	3.6	5
113	Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 902	5.3	5
112	Targeted treatments in advanced renal cell carcinoma: focus on axitinib. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2014</b> , 7, 107-16	2.1	5
111	First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 19-21	4.6	5
110	Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials. <i>Future Oncology</i> , <b>2013</b> , 9, 1451-8	3.6	5
109	Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 768-73	8.9	5
108	Imatinib administration in two patients with liver metastases from GIST and severe jaundice. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 1403-4	8.7	5
107	Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer. <i>Oncology</i> , <b>2002</b> , 63, 115-23	3.6	5
106	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors <b>2021</b> , 9,		5
105	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 34-43.e6	3.8	5

104	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , <b>2020</b> , 25, 780-786	5.7	5
103	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 31-40	7.5	5
102	Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. <i>TH Open</i> , <b>2021</b> , 5, e56-e65	2.7	5
101	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. <i>Future Oncology</i> , <b>2017</b> , 13, 1677-1683	3.6	4
100	Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients. <i>Oncology</i> , <b>2015</b> , 88, 133-8	3.6	4
99	Combination therapies for patients with metastatic renal cell carcinoma. <i>Lancet Oncology</i> , <b>2018</b> , 19, 281-283	21.7	4
98	Update on medical treatment of small intestinal neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 969-76	3.5	4
97	Trastuzumab cardiac toxicity: a problem we put our heart into. <i>Tumori</i> , <b>2016</b> , 102, 1-5	1.7	4
96	Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience. <i>Tumori</i> , <b>2016</b> , 102, 501-507	1.7	4
95	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e81-90	3.3	4
94	Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 1025-34	3.9	4
93	Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity. <i>Personalized Medicine</i> , <b>2014</b> , 11, 259-262	2.2	4
92	Biological insights into BRAF mutations in melanoma patient: Not mere therapeutic targets. <i>Oncolmmunology</i> , <b>2013</b> , 2, e25594	7.2	4
91	Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. <i>Chemotherapy</i> , <b>2011</b> , 57, 217-24	3.2	4
90	Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum. <i>Cancers</i> , <b>2012</b> , 4, 808-20	6.6	4
89	Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 138-9	8.9	4
88	Induction chemotherapy followed by simultaneous hyperfractionated radiochemotherapy in advanced head and neck cancer. A pilot study. <i>Strahlentherapie Und Onkologie</i> , <b>1998</b> , 174, 457-61	4.3	4
87	Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 1345-6; author reply 1346-7	9.7	4

86	A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. <i>Lung Cancer</i> , <b>2006</b> , 54, 359-64	5.9	4
85	Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 921-2; author reply 922	2.2	4
84	Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities. <i>Tumori</i> , <b>2013</b> , 99, e148-51	1.7	4
83	DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. <i>Cells</i> , <b>2020</b> , 9,	7.9	4
82	ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?. <i>Thrombosis Research</i> , <b>2020</b> , 194, 176-177	8.2	4
81	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients <b>2021</b> , 9,		4
80	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102583	2.2	4
79	Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. <i>Tumori</i> , <b>2012</b> , 98, 279-86	1.7	4
78	Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study. <i>Breast Cancer</i> , <b>2017</b> , 24, 635-641	3.4	3
77	Prognosis of women with early breast cancer and PIK3CA mutations. <i>Breast</i> , <b>2015</b> , 24, 283-4	3.6	3
76	Aprepitant versus dexamethasone for delayed emesis: what is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2185-6	2.2	3
75	Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial. <i>Oncology</i> , <b>2013</b> , 84, 371-7	3.6	3
74	Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib. <i>Urologia Internationalis</i> , <b>2009</b> , 82, 196-202	1.9	3
73	Tackling off-label use of anticancer drugs. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2800; author reply 2801	2.2	3
72	Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: a survey from the Italian National Monitoring Centre for Clinical Trials. <i>Trials</i> , <b>2008</b> , 9, 46	2.8	3
71	Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 461-2; author reply 462-3	9.7	3
70	Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7243-4; author reply 7244	2.2	3
69	Is there a Real Advantage in Utilizing Central Venous Ports in Oncology Surgery? An Analysis of the Cost-Effectiveness Ratio. <i>Tumori</i> , <b>2001</b> , 87, 74-75	1.7	3

68	Pharmacokinetics of Oral Doxifluridine in Patients with Colorectal Cancer. <i>Tumori</i> , <b>1999</b> , 85, 47-50	1.7	3
67	Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 218-218	2.2	3
66	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 160, 103299	7	3
65	EGFR Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 1561-1569	9.7	3
64	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 161-169	4.9	3
63	Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. <i>Tumori</i> , <b>2019</b> , 105, 465-473	1.7	2
62	Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. <i>Clinical and Translational Oncology</i> , <b>2015</b> , 17, 530-8	3.6	2
61	A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
60	Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2016</b> , 468, 451-61	5.1	2
59	Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 859-63	2.2	2
58	Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 486-8	4.6	2
57	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. <i>Clinical and Translational Oncology</i> , <b>2013</b> , 15, 582-6	3.6	2
56	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. <i>Therapeutic Advances in Urology</i> , <b>2015</b> , 7, 59-68	3.2	2
55	Butterfly and renal cell cancer: out of chaos comes order. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3083	2.2	2
54	Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1415-6	10.3	2
53	To target or not to target, that is the question. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1254	2.2	2
52	A 15-min premedication for 1-h paclitaxel infusion: optimizing patients' care. <i>Lung Cancer</i> , <b>2007</b> , 58, 300-4.9		2
51	Target-treatment and patients' selection: can we still neglect the timing of tissue collection?. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6274-5; author reply 6275-6	2.2	2

50	Very low acute toxicity of three fractions per day accelerated radiotherapy given after induction chemotherapy and surgery in stage III non-small cell lung cancer. <i>Lung Cancer</i> , <b>2000</b> , 30, 149-50	5.9	2
49	Activity and Tolerability of Courses of Intra-Arterial Chemotherapy Followed by Chemoembolization in Unresectable Hepatocellular Carcinoma. <i>Tumori</i> , <b>1998</b> , 84, 673-676	1.7	2
48	Adjuvant Chemotherapy for Cancer of Gastrointestinal Tract: A Critical Review. <i>Tumori</i> , <b>1992</b> , 78, 228-234.	4.7	2
47	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 1-7	3.5	2
46	Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9065-9065	2.2	2
45	A phase 2 prospective trial of cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2) clinical trial information NCT03354884.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4571-4571	2.2	2
44	Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. <i>Clinical and Translational Medicine</i> , <b>2021</b> , 11, e434	5.7	2
43	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up. <i>Case Reports in Oncology</i> , <b>2016</b> , 9, 432-439	1	2
42	In reply. <i>Oncologist</i> , <b>2015</b> , 20, e5	5.7	1
41	Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. <i>International Journal of Colorectal Disease</i> , <b>2015</b> , 30, 429-30	3	1
40	Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. <i>Tumori</i> , <b>2021</b> , 107, 542-549	1.7	1
39	Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse. <i>Clinical Oncology</i> , <b>2014</b> , 26, 174	2.8	1
38	Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-33. <i>European Urology</i> , <b>2012</b> , 62, e5-6; author reply e7-8	10.2	1
37	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. <i>Clinical Interventions in Aging</i> , <b>2015</b> , 10, 127-33	4	1
36	FOLFIRI with cetuximab or bevacizumab: FIRE-3. <i>Lancet Oncology</i> , <b>2014</b> , 15, e581	21.7	1
35	Adjuvant treatment of colorectal cancer in the elderly: Where do we come from and where are we going?. <i>Journal of Solid Tumors</i> , <b>2012</b> , 2,	0.3	1
34	Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1747-8	10.3	1
33	Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2771-2772	10.3	1

32	Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1124-30	8.9	1
31	Adjuvant chemotherapy in new stage II pN0 non-small cell lung cancer: a new issue for a case-by-case decision making process. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 754	8.9	1
30	CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1850	10.3	1
29	Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2603-4; author reply 2605	2.2	1
28	Pharmacokinetic (PK) and pharmacodynamic (PD) analysis from a phase I study of PF-03446962, a fully human mab against ALK1, a TGF-beta receptor involved in tumor angiogenesis.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e13606-e13606	2.2	1
27	New perspectives in advanced genitourinary malignancies. <i>Tumori</i> , <b>2012</b> , 98, 267-9	1.7	1
26	Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211006960	5.4	1
25	Update on Therapeutic Strategy in Lung Carcinoids. <i>Journal of Cancer Therapy</i> , <b>2013</b> , 04, 1466-1471	0.2	1
24	Pazopanib induces dramatic but transient contraction of myeloid suppression compartment in favor of adaptive immunity		1
23	Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, E403-7	2.6	1
22	Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer. <i>Breast</i> , <b>2016</b> , 27, 187-8	3.6	1
21	Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 261-268	3.8	1
20	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. <i>Future Oncology</i> , <b>2019</b> , 15, 3015-3024	3.6	0
19	Reply to Letter to the Editor: "Toxic epidermal necrolysis in patients with malignancies" by G. Gravante, G. Esposito, M. Marianetti, D. Delogu, G. Sconocchia & A. Montone (doi:10.1093/annonc/mdl089). <i>Annals of Oncology</i> , <b>2006</b> , 17, 1601-1602	10.3	0
18	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.. <i>Oncologist</i> , <b>2022</b> , 27, e29-e36	5.7	0
17	Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 169, 103532	7	0
16	SMO mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1940-1951	4.4	0
15	Trends in exposure to multiple lines of treatment and survival of patients with metastatic renal cell carcinoma: A real-world analysis.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16064-e16064	2.2	0

14	Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9032-9032	2.2	0
13	Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 857515	5.3	0
12	"Systemic strategy at the patient's service": a congress report on supportive care in oncology. <i>Tumori</i> , <b>2017</b> , 0	1.7	
11	Right pelvic mass in a patient with a radically resected carcinoid of the appendix. <i>Gut</i> , <b>2009</b> , 58, 1200, 1259	19.2	
10	mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1940-1951	4.4	
9	Pharmacogenetics in Oncology <b>2006</b> , 129-153		
8	Multidisciplinary Approach of Prostate Cancer Patients <b>2017</b> , 281-293		
7	Whole-exome sequencing in radically resected gastric cancer (GC): Analysis of patients (pts) with poor prognostic factors from the Italian Trial of Adjuvant Chemotherapy Adenocarcinoma (ITACA-S) trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 64-64	2.2	
6	Safety and antitumor activity of weekly carboplatin plus paclitaxel in metastatic breast cancer: A ten years, single-institution, retrospective analysis.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e12556-e12556 <sup>2</sup>	2.2	
5	Pharmacokinetic modeling and simulation (PK M&S) supported dose escalation of IPF-03446962, a monoclonal antibody (mAb) against activin receptor like kinase 1, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2595-2595	2.2	
4	Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma. <i>Tumori</i> , <b>2014</b> , 100, e282-e285	1.7	
3	A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5052-5052	2.2	
2	Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4167-TPS4167	2.2	
1	Atypical Mutations in Metastatic Colorectal Cancer.. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-11	3.6	